UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Journal of allergy and clinical immunology, 2016-05, Vol.137 (5), p.1610-1613.e7

2016

Volltextzugriff (PDF)

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

European heart journal, 2013-08, Vol.34 (31), p.2481-2489

2013

Volltextzugriff (PDF)

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Journal of allergy and clinical immunology, 2016-12, Vol.138 (6), p.1712-1715

2016

Volltextzugriff (PDF)

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

The Lancet (British edition), 2016-01, Vol.387 (10016), p.349-356

2016

Volltextzugriff (PDF)

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

The American heart journal, 2011-02, Vol.161 (2), p.261-268.e2

2011

Volltextzugriff (PDF)

Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

The New England journal of medicine, 2004-09, Vol.351 (13), p.1285-1295

2004

Volltextzugriff (PDF)

Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention

Journal of the American Heart Association, 2023-01, Vol.12 (1), p.e025666-e025666

2023

Volltextzugriff (PDF)

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

Circulation (New York, N.Y.), 2010-08, Vol.122 (6), p.597-602

2010

Volltextzugriff (PDF)

Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial

The American heart journal, 2020-05, Vol.223, p.84-86

2020

Volltextzugriff (PDF)

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Arteriosclerosis, thrombosis, and vascular biology, 2010-03, Vol.30 (3), p.382-387

2010

Volltextzugriff (PDF)

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

The New England journal of medicine, 2003-11, Vol.349 (20), p.1893-1906

2003

Volltextzugriff (PDF)

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

European heart journal, 2011-10, Vol.32 (19), p.2412-2419

2011

Volltextzugriff (PDF)

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

European heart journal. Acute cardiovascular care, 2019-09, Vol.8 (6), p.520-526

2019

Volltextzugriff (PDF)

Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction

European journal of heart failure, 2006-10, Vol.8 (6), p.591-598

2006

Volltextzugriff (PDF)

Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study

European heart journal, 2009-01, Vol.30 (1), p.56-65

2009

Volltextzugriff (PDF)

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

Cardiovascular drugs and therapy, 2017-08, Vol.31 (4), p.445-458

2017

Volltextzugriff (PDF)

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Journal of hypertension, 2007-09, Vol.25 (9), p.1921-1926

2007

Volltextzugriff (PDF)

Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study

EuroIntervention, 2014-08, Vol.10 (4), p.431-438

2014

Volltextzugriff (PDF)

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction

Hypertension (Dallas, Tex. 1979), 2008-01, Vol.51 (1), p.48-54

2008

Volltextzugriff (PDF)

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Journal of cardiovascular translational research, 2010-12, Vol.3 (6), p.704-716

2010

Volltextzugriff (PDF)

Sustained Inhibition of Factor IXa by Subcutaneous RB006 With Active Reversal: First-in-Human Experience With the REG2 System

Chest, 2010-10, Vol.138 (4), p.851A-851A

2010

Volltextzugriff (PDF)

Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial

The Journal of invasive cardiology, 2013-11, Vol.25 (11), p.593-599

2013

Volltextzugriff (PDF)

Response to Letter Regarding Article, “Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both”

Circulation (New York, N.Y.), 2011-05, Vol.123 (18)

2011

Volltextzugriff (PDF)

The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty

The American heart journal, 1992-06, Vol.123 (6), p.1445-1451

1992

Volltextzugriff (PDF)

Valsartan improves early morning adn 24-hour heart rate variability

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.109-109

2003

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction

Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Sustained Inhibition of Factor IXa by Subcutaneous RB006 With Active Reversal: First-in-Human Experience With the REG2 System

Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial

Response to Letter Regarding Article, “Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both”

The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty

Valsartan improves early morning adn 24-hour heart rate variability

Suchergebnisse filtern